APG Asset Management N.V. Grows Stake in Royalty Pharma plc (NASDAQ:RPRX)

APG Asset Management N.V. grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 382,906 shares of the biopharmaceutical company’s stock after purchasing an additional 17,406 shares during the period. APG Asset Management N.V.’s holdings in Royalty Pharma were worth $9,433,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in RPRX. Brooklyn Investment Group increased its position in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP grew its stake in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 877 shares during the last quarter. Riverview Trust Co increased its holdings in shares of Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp boosted its stake in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. boosted its stake in Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 1,003 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

RPRX has been the topic of several research analyst reports. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of “Buy” and a consensus price target of $41.60.

Royalty Pharma Trading Down 3.3 %

NASDAQ RPRX opened at $31.21 on Friday. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a market capitalization of $17.99 billion, a PE ratio of 21.52, a P/E/G ratio of 2.31 and a beta of 0.50. The company has a fifty day moving average of $32.48 and a 200 day moving average of $29.11.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.